Common use of Buyer Preamble Clause in Contracts

Buyer Preamble. Buyer Documents 4.2 Closing 1.6(a) Closing Balance Sheet 1.3(b) Closing Date 1.6(a) Company Recitals Company Transaction Payments 2.22 Disclosure Schedule 2 Deferred Payment Calculation 1.7(b) Deferred Payment Calculation Objection Notice 1.7(d) Effective Time 1.6(a) Estimated Adjusted Working Capital 1.3(a) Financial Statements 2.4 Flamel Preamble Foreign Plan 2.9(d) Hycet Product Deferred Consideration 1.7(a) Hycet Product Deferred Payment 1.7(a) Launch Products Deferred Consideration 1.7(a) Launch Products Deferred Payment 1.7(a) Leased Real Property 2.11 Loan Agreement 1.2(a) Material Contract 2.17(a) Note 1.2(a) Pension Plan 2.9(d) Product Suppliers 2.16 Reviewing Accountant 1.3(e) Seller Preamble Seller Documents 3.2 Units Recitals Warrant Agreement 1.2(b) Warrant Consideration 1.2(b) Working Capital Objection Notice 1.3(d) [Confidential Treatment Requested] DISCLOSURE SCHEDULES TO THE MEMBERSHIP INTEREST PURCHASE AGREEMENT by and among ÉCLAT HOLDINGS, LLC, a Delaware limited liability company; ÉCLAT PHARMACEUTICALS, LLC, a Delaware limited liability company; FLAMEL TECHNOLOGIES, SA, a société anonyme organized under the laws of the Republic of France; and FLAMEL US HOLDINGS, INC., a Delaware corporation. Dated as of March 13, 2012 Capitalized terms used in these Disclosure Schedules that are not otherwise defined herein shall have the respective meanings ascribed to them in the Membership Interest Purchase Agreement referred to above. [Confidential Treatment Requested] Schedule 1.3(a) Estimated Adjusted Working Capital Cash $ 1,629,502 Inventory $ 35,551 Accounts Receivable $ 262,524 Prepaid Assets $ 433,466 Other Current Assets $ 14,713 Total $ 2,375,756 Accounts Payable $ 235,617 Accrued Operating Liabilities $ 98,968 Return Rebate and Chargeback $ 40,000 Total $ 374,585 Adjusted Working Capital $ 2,001,171 [Confidential Treatment Requested] Schedule 1.8 Warrant Consideration

Buyer Preamble. Buyer Documents 4.2 Closing 1.6(aEquity Securities Section 2.08 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. Schedules (or similar attachments) Closing Balance Sheet 1.3(b) Closing Date 1.6(a) Company Recitals Company Transaction Payments 2.22 Disclosure Schedule 2 Deferred Payment Calculation 1.7(b) Deferred Payment Calculation Objection Notice 1.7(d) Effective Time 1.6(a) Estimated Adjusted Working Capital 1.3(a) Financial Statements 2.4 Flamel Preamble Foreign Plan 2.9(d) Hycet Product Deferred Consideration 1.7(a) Hycet Product Deferred Payment 1.7(a) Launch Products Deferred Consideration 1.7(a) Launch Products Deferred Payment 1.7(a) Leased Real Property 2.11 Loan Agreement 1.2(a) Material Contract 2.17(a) Note 1.2(a) Pension Plan 2.9(d) Product Suppliers 2.16 Reviewing Accountant 1.3(e) Seller Preamble Seller Documents 3.2 Units Recitals Warrant Agreement 1.2(b) Warrant Consideration 1.2(b) Working Capital Objection Notice 1.3(d) [Confidential Treatment Requested] DISCLOSURE SCHEDULES TO THE MEMBERSHIP INTEREST PURCHASE AGREEMENT by referred to and among ÉCLAT HOLDINGS, LLC, a Delaware limited liability company; ÉCLAT PHARMACEUTICALS, LLC, a Delaware limited liability company; FLAMEL TECHNOLOGIES, SA, a société anonyme organized under the laws of the Republic of France; and FLAMEL US HOLDINGS, INC., a Delaware corporation. Dated as of March 13, 2012 Capitalized terms used in these Disclosure Schedules that are not otherwise defined listed herein shall have been omitted pursuant to Item 601(b)(2) of Regulation S-K. A copy of any omitted schedule (or similar attachment) will be furnished to the respective meanings ascribed Commission upon request. Term Section Buyer SEC Documents 4.09 Capital Raise 4.07 Closing 2.02 Company Balance Sheet 3.08 Current Representation 10.13 Damages 9.02 Data Package 6.01 Designated Person 10.13 Exclusivity Period 6.01 Generic Version 6.02 Indemnified Party 9.03 Indemnifying Party 9.03 Independent Accounting Firm 2.07 Leave Recipient 8.01 Loss 7.02 Market Price 2.08 Net Liabilities 2.04 Net Sales 6.02 Patent Service Provider 5.09 Permitted Liens 3.14 Post-Closing Capital Raise 2.08 Post-Closing Payment Date 2.08 Post-Closing Representation 10.13 Potential Contributor 9.06 Purchase Price 2.01 [**] 8.07 Roche Basel Preamble Roche Nutley Preamble Royalty Period 6.02 Seller Marks 5.05 Sellers Preamble Tax Benefit 7.06 Term Sheet Period 6.01 Total Consideration 2.07 Third Party Claim 9.03 Transferred Employee 8.01 WARN 8.09 Warranty Breach 9.02 [**] = Portions of this exhibit have been omitted pursuant to them in a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Membership Interest Purchase Agreement Commission. Schedules (or similar attachments) referred to above. [Confidential Treatment Requested] Schedule 1.3(aand listed herein shall have been omitted pursuant to Item 601(b)(2) Estimated Adjusted Working Capital Cash $ 1,629,502 Inventory $ 35,551 Accounts Receivable $ 262,524 Prepaid Assets $ 433,466 Other Current Assets $ 14,713 Total $ 2,375,756 Accounts Payable $ 235,617 Accrued Operating Liabilities $ 98,968 Return Rebate and Chargeback $ 40,000 Total $ 374,585 Adjusted Working Capital $ 2,001,171 [Confidential Treatment Requested] Schedule 1.8 Warrant Considerationof Regulation S-K. A copy of any omitted schedule (or similar attachment) will be furnished to the Commission upon request.

Buyer Preamble. Buyer Documents 4.2 Closing 1.6(aStatement 2.02(b)(i) Buyer Cure Period 10.01(f) Buyer SEC Reports 5.07 Claim Certificate 11.04(a) Claim Dispute Notice 11.04(b) Closing Section 2.01(d) Closing Balance Sheet 1.3(b2.02(b)(i) Closing Date 1.6(aSection 2.01(d) Closing Option Consideration 2.03(a) Company Recitals Preamble Company Transaction Payments 2.22 Disclosure Schedule 2 Deferred Payment Calculation 1.7(bBoard of Directors 3.04(f) Deferred Payment Calculation Objection Notice 1.7(dCompany Closing Certificate 9.02(e)(vii) Effective Time 1.6(aCompany Cure Period 10.01(e) Estimated Adjusted Working Capital 1.3(aCompany Inbound IP License 3.08(a)(iii) Financial Statements 2.4 Flamel Preamble Foreign Plan 2.9(d) Hycet Product Deferred Consideration 1.7(a) Hycet Product Deferred Payment 1.7(a) Launch Products Deferred Consideration 1.7(a) Launch Products Deferred Payment 1.7(a) Company Insurance Policies Section 3.16 Company Leased Real Property 2.11 Loan Agreement 1.2(a3.11(a) Company Outbound IP License 3.08(a)(iv) Company Registered IP 3.13(b) Company Securities 3.04(c) Company Shareholder Approval Recitals Company Software 3.13(m) Confidential Information 3.13(h) Consideration Spreadsheet 6.05 D&O Indemnified Persons 7.04(a) D&O Tail Policy 7.04(b) Data Room 1.02(l) Designated Accounting Firm 2.02(b)(v) Enforceability Exceptions 3.01(a) Equityholder Representative 12.01(a) Equityholder Representative Expense Account 2.04(e) Escrow Account 2.04(d) Estimated Closing Cash 2.02(a) Estimated Closing Indebtedness 2.02(a) Estimated Closing Working Capital 2.02(a) Estimated Unpaid Company Transaction Expenses 2.02(a) Excess Consideration 2.02(b)(vi) Exchange Agent 2.04(a) Expert Calculations 2.02(b)(v) FCPA 3.23 Financial Statements 3.05(a) FR Expiration Date 11.01(a) General Expiration Date 11.01(a) Holdback Period 11.04(g) Interim Period 6.01 Invoice 6.06 IT Systems 3.14(a) Key Employees Recitals Malicious Code 3.13(n) Management Accounts 3.05(a) Material Contract 2.17(a3.08(a) Note 1.2(aMaterial Customer 3.21(a) Pension Plan 2.9(dMaterial Supplier 3.21(b) Product Suppliers 2.16 Reviewing Accountant 1.3(eNon-Competition and Non-Solicitation Agreement Recitals Offer Letters Recitals Option Acknowledgement 2.03(c) Seller Option Consideration 2.03(a) Other Interested Party 6.02 Payoff Letter 6.06 PCA 3.23 PCI DSS Section 3.15(f) Permits 3.17 Permitted Liens Section 3.11(d)(iv) Privacy Agreements 3.15(a) Real Property Lease 3.11(c) Related Person 3.22 Releasee 6.07 Releasor 6.07 Review Period 2.02(b)(iii) Restricted Share Agreements Recitals Restricted Shareholders Recitals Restricted Shares Recitals Rule 144 1.01(a) Sale 2.01(a) Sellers Preamble Seller Documents 3.2 Units Service Agreements 3.21(c) Share Closing Deliverables 2.04(b) Share Transfer Form 2.04(b)(ii) Shares Recitals Warrant Agreement 1.2(bShortfall Consideration 2.02(b)(vi) Warrant Consideration 1.2(bTax Contest 8.03 Third Party Claim 11.06 Transfer Taxes 8.06 U.S. GAAS Audit Opinion 1.01(a) Working Capital Objection Notice 1.3(d) [Confidential Treatment Requested] DISCLOSURE SCHEDULES TO THE MEMBERSHIP INTEREST PURCHASE AGREEMENT by and among ÉCLAT HOLDINGS, LLC, a Delaware limited liability company; ÉCLAT PHARMACEUTICALS, LLC, a Delaware limited liability company; FLAMEL TECHNOLOGIES, SA, a société anonyme organized under the laws of the Republic of France; and FLAMEL US HOLDINGS, INC., a Delaware corporation. Dated as of March 13, 2012 Capitalized terms used in these Disclosure Schedules that are not otherwise defined herein shall have the respective meanings ascribed to them in the Membership Interest Purchase Agreement referred to above. [Confidential Treatment Requested] Schedule 1.3(a) Estimated Adjusted Working Capital Cash $ 1,629,502 Inventory $ 35,551 Accounts Receivable $ 262,524 Prepaid Assets $ 433,466 Other Current Assets $ 14,713 Total $ 2,375,756 Accounts Payable $ 235,617 Accrued Operating Liabilities $ 98,968 Return Rebate and Chargeback $ 40,000 Total $ 374,585 Adjusted Working Capital $ 2,001,171 [Confidential Treatment Requested] Schedule 1.8 Warrant ConsiderationUnresolved Claims 11.04(g)